Lerodalcibep Injection 300 mg/1.2 mL Suppliers & Bulk Manufacturers

Available Forms: Pre-filled syringe, autoinjector (subcutaneous)

Available Strengths: 300 mg/1.2 mL

Reference Brands: Lerochol (LIB Therapeutics)

Category: Heart Disorder

Lerodalcibep (Lerochol, LIB Therapeutics) is a once-monthly PCSK9-blocking injection that lowers LDL cholesterol, approved by the US FDA in December 2025. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.

Product Description:

Lerodalcibep is a biologic PCSK9 inhibitor. Like evolocumab and alirocumab it stops PCSK9 from destroying LDL receptors in the liver, so more LDL cholesterol is cleared from the blood. It is built differently from those antibodies and stays in the body longer, so it is given once a month as a single 300 mg injection under the skin.

The US FDA approved lerodalcibep as Lerochol in December 2025 to lower LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, usually with a statin. A pre-filled syringe came first and an autoinjector was added in August 2026.

Sourcing and licensing notes. Lerodalcibep is patented and there is no biosimilar. Other PCSK9 options on PharmaTradz include evolocumab, inclisiran and the new oral enlicitide. We confirm registration status for each destination before quoting.